{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:08:57Z","timestamp":1788754137963,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T00:00:00Z","timestamp":1764806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100031283","name":"Sanofi France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031283","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-25726-1","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:07:49Z","timestamp":1764889669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modelling the epidemiological impact and cost-effectiveness of possible changes to the meningococcal vaccination schedule for adolescents and young adults in the United States"],"prefix":"10.1186","volume":"26","author":[{"given":"Thomas","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Cristeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie","family":"Upegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen P.","family":"Neary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corwin A.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Galarza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"Clay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,4]]},"reference":[{"key":"25726_CR1","unstructured":"Centers for Disease Control and Prevention. Meningococcal Disease Symptoms and Complications [https:\/\/www.cdc.gov\/meningococcal\/symptoms\/index.html]. Accessed 25 Oct 2024."},{"issue":"1","key":"25726_CR2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40121-021-00546-z","volume":"11","author":"J Shen","year":"2022","unstructured":"Shen J, Bouee S, Aris E, Emery C, Beck EC. Long-Term mortality and state financial support in invasive meningococcal Disease-Real-World data analysis using the French National claims database (SNIIRAM). Infect Dis Ther. 2022;11(1):249\u201362.","journal-title":"Infect Dis Ther"},{"key":"25726_CR3","unstructured":"Centers for Disease Control and Prevention. Cases of Meningococcal Disease Are Increasing in the United States [https:\/\/www.cdc.gov\/ncird\/whats-new\/meningococcal-disease-cases-increasing-us.html]. Accessed 7 February 2025."},{"key":"25726_CR4","unstructured":"World Health Organization: Meningitis, Symptoms. [https:\/\/www.who.int\/health-topics\/meningitis#tab=tab_2]. Accessed 31 May 2025."},{"issue":"4","key":"25726_CR5","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","volume":"7","author":"KJ Olbrich","year":"2018","unstructured":"Olbrich KJ, M\u00fcller D, Schumacher S, Beck E, Meszaros K, Koerber F. Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers. Infect Dis Ther. 2018;7(4):421\u201338.","journal-title":"Infect Dis Ther"},{"issue":"1","key":"25726_CR6","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1186\/s12889-022-13342-2","volume":"22","author":"J Shen","year":"2022","unstructured":"Shen J, Begum N, Ruiz-Garcia Y, Martinon-Torres F, Bekkat-Berkani R, Meszaros K. Range of invasive meningococcal disease sequelae and health economic application - a systematic and clinical review. BMC Public Health. 2022;22(1):1078.","journal-title":"BMC Public Health"},{"key":"25726_CR7","unstructured":"Centers for Disease Control and Prevention. About Meningococcal Disease [https:\/\/www.cdc.gov\/meningococcal\/about\/index.html]. Accessed 25 October 2024."},{"key":"25726_CR8","unstructured":"Centers for Disease Control and Prevention. Meningococcal Disease Surveillance and Trends [https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/index.html]. Accessed 30 May 2025."},{"key":"25726_CR9","unstructured":"Centers for Disease Control and Prevention. Emergency Preparedness and Response. Increase in Invasive Serogroup Y Meningococcal Disease in the United States [https:\/\/emergency.cdc.gov\/han\/2024\/han00505.asp]. Accessed 31 May 2025."},{"key":"25726_CR10","unstructured":"Centers for Disease Control and Prevention. Public Health Strategies for Antibiotic-resistant Neisseria meningitidis [https:\/\/www.cdc.gov\/meningococcal\/php\/antibiotic-resistant\/index.html]. Accessed 2 May 2025."},{"key":"25726_CR11","unstructured":"Centers for Disease Control and Prevention: Enhanced Meningococcal Disease Surveillance Report. 2019 [https:\/\/stacks.cdc.gov\/view\/cdc\/140466]. Accessed 31 May 2025."},{"key":"25726_CR12","unstructured":"Centers for Disease Control and Prevention: Enhanced Meningococcal Disease Surveillance Report. 2020 [https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2020.pdf]. Accessed 31 May 2025."},{"key":"25726_CR13","unstructured":"Centers for Disease Control and Prevention: Enhanced Meningococcal Disease Surveillance Report. 2021 [https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2021.pdf]. Accessed 31 May 2025."},{"key":"25726_CR14","unstructured":"Centers for Disease Control and Prevention: Enhanced Meningococcal Disease Surveillance Report. 2022 [https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2022-508.pdf]. Accessed 31 May 2025."},{"issue":"12","key":"25726_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"25726_CR16","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.jinf.2024.01.002","volume":"88","author":"M McMillan","year":"2024","unstructured":"McMillan M, Mohammed H, Bednarz J, Leong LEX, Lawrence A, Sullivan TR, Maiden MCJ, Marshall HS. Longitudinal study of meningococcal carriage in adolescents and young adults in South Australia 2017\u20132020. J Infect. 2024;88(2):149\u201357.","journal-title":"J Infect"},{"issue":"5","key":"25726_CR17","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1080\/21645515.2016.1268304","volume":"13","author":"RT Tekin","year":"2017","unstructured":"Tekin RT, Dinleyici EC, Ceyhan M, Karbuz A, Salman N, Sutcu M, Kurugol Z, Balliel Y, Celik M, Hacimustafaoglu M, et al. The prevalence, serogroup distribution and risk factors of meningococcal carriage in adolescents and young adults in Turkey. Hum Vaccin Immunother. 2017;13(5):1182\u20139.","journal-title":"Hum Vaccin Immunother"},{"key":"25726_CR18","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1017\/S0950268820000734","volume":"148","author":"SV Watle","year":"2020","unstructured":"Watle SV, Caugant DA, Tunheim G, Bekkevold T, Laake I, Brynildsrud OB, Naess LM. Meningococcal carriage in Norwegian teenagers: strain characterisation and assessment of risk factors. Epidemiol Infect. 2020;148:e80.","journal-title":"Epidemiol Infect"},{"issue":"12","key":"25726_CR19","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.cmi.2022.07.004","volume":"28","author":"JP Carr","year":"2022","unstructured":"Carr JP, MacLennan JM, Plested E, Bratcher HB, Harrison OB, Aley PK, Bray JE, Camara S, Rodrigues CMC, Davis K, et al. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clin Microbiol Infect. 2022;28(12):1649. e1641-1649 e1648.","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"25726_CR20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1093\/infdis\/jiu679","volume":"211","author":"LH Harrison","year":"2015","unstructured":"Harrison LH, Shutt KA, Arnold KE, Stern EJ, Pondo T, Kiehlbauch JA, Myers RA, Hollick RA, Schmink S, Vello M, et al. Meningococcal carriage among Georgia and Maryland high school students. J Infect Dis. 2015;211(11):1761\u20138.","journal-title":"J Infect Dis"},{"issue":"6","key":"25726_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/jama.286.6.694","volume":"286","author":"LH Harrison","year":"2001","unstructured":"Harrison LH, Pass MA, Mendelsohn AB, Egri M, Rosenstein NE, Bustamante A, Razeq J, Roche JC. Invasive meningococcal disease in adolescents and young adults. JAMA. 2001;286(6):694\u20139.","journal-title":"JAMA"},{"key":"25726_CR22","unstructured":"Centers for Disease Control and Prevention. Current CDC Vaccine Price List. Prices last reviewed\/updated: February 1, 2025 [https:\/\/www.cdc.gov\/vaccines-for-children\/php\/awardees\/current-cdc-vaccine-price-list.html]. Accessed 11 March 2025."},{"key":"25726_CR23","unstructured":": GSK, Penmenvy. GSK\u2019s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY [https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/penmenvy-gsk-s-5-in-1-meningococcal-vaccine-approved-by-us-fda-to-help-protect-against-menabcwy\/]. Accessed 26 February 2025."},{"key":"25726_CR24","unstructured":"Centers for Disease Control and Prevention. Child Immunization Schedule Notes [https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-notes.html#note-mening]. Accessed 31 May 2025."},{"key":"25726_CR25","unstructured":"Centers for Disease Control and Prevention: Child and Adolescent Immunization Schedule by Age. Recommendations for Ages 18 Years or Younger, United States. 2025 [https:\/\/www.cdc.gov\/vaccines\/hcp\/imz-schedules\/child-adolescent-age.html]. Accessed 31 May 2025."},{"issue":"33","key":"25726_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.15585\/mmwr.mm7333a1","volume":"73","author":"C Pingali","year":"2024","unstructured":"Pingali C, Yankey D, Chen M, Elam-Evans LD, Markowitz LE, DeSisto CL, Schillie SF, Hughes M, Valier MR, Stokley S, et al. National vaccination coverage among adolescents aged 13\u201317 Years - National immunization Survey-Teen, united States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(33):708\u201314.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"25726_CR27","doi-asserted-by":"publisher","first-page":"345","DOI":"10.15585\/mmwr.mm7315a4","volume":"73","author":"JP Collins","year":"2024","unstructured":"Collins JP, Crowe SJ, Ortega-Sanchez IR, Bahta L, Campos-Outcalt D, Loehr J, Morgan RL, Poehling KA, McNamara LA. Use of the Pfizer pentavalent meningococcal vaccine among persons Aged\u2009\u2265\u200910 years: recommendations of the advisory committee on immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):345\u201350.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"25726_CR28","unstructured":"Schillie S. May : GSK Pentavalent (MenABCWY) Vaccine: Review of Updated EtR and Work Group Considerations [https:\/\/www.cdc.gov\/acip\/downloads\/slides-2025-04-15-16\/02-Schillie-mening-508.pdf]. Accessed 30 2025."},{"key":"25726_CR29","unstructured":"Schillie S. Revising the Adolescent Meningococcal Vaccine Schedule: Term of Reference and Considerations, February 29, 2024 [https:\/\/stacks.cdc.gov\/view\/cdc\/148680]. Accessed 15 May 2024."},{"key":"25726_CR30","unstructured":"Schillie S. Work Group Considerations Regarding MenABCWY Vaccine and Discussion of Potential Risk Groups for MenB Vaccination, June 28, 2024 [https:\/\/stacks.cdc.gov\/view\/cdc\/157876]. Accessed July 15 2024."},{"issue":"1","key":"25726_CR31","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1186\/s12889-025-21953-8","volume":"25","author":"E Langevin","year":"2025","unstructured":"Langevin E, Robertson C, Galarza K, Dogu A, Cristeau O, Clay E, Wu J, Shin T. Understanding the value of meningococcal vaccination for adolescents and young adults in the united states: insights from a steady-state modelling approach. BMC Public Health. 2025;25(1):1863.","journal-title":"BMC Public Health"},{"key":"25726_CR32","unstructured":"Ortega-Sanchez IR. The Cost-effectiveness of a Potential Pentavalent Meningococcal Conjugate Vaccine (Men ABCWY) versus the Current Men ACWY and Men B vaccines for US Adolescents. ACIP meeting, June 23, 2023 [https:\/\/www.cdc.gov\/acip\/downloads\/slides-2023-06-21-23\/02-Mening-Ortega-Sanchez-508.pdf]. Accessed 28 October 2024."},{"key":"25726_CR33","unstructured":"Ortega-Sanchez IR. Economics of Potential Pentavalent Meningococcal Conjugate Vaccine (MenABCWY) versus the Current MenACWYand MenBvaccines for US Adolescents. Meningococcal ACIP Meeting, October 25, 2023 [https:\/\/stacks.cdc.gov\/view\/cdc\/134697\/cdc_134697_DS1.pdf]. Accessed 28 October 2024."},{"key":"25726_CR34","unstructured":"Dong X, Leidner AJ, Schillie S, McNamara LA. Economic Analyses of GSK MenABCWY Vaccinations among Adolescents in the United States [https:\/\/www.cdc.gov\/acip\/downloads\/slides-2024-10-23-24\/02-Mening-Dong-508.pdf]. Accessed 11 February 2025."},{"key":"25726_CR35","unstructured":"United States Census Bureau. Population and Housing Unit Estimates Datasets [https:\/\/www.census.gov\/programs-surveys\/popest\/data\/data-sets.2000.List_1725564412.html]. Accessed 15 May 2024."},{"key":"25726_CR36","unstructured":"United States Census Bureau. American Community Survey [https:\/\/data.census.gov\/table\/ACSDP5Y2022.DP05?q=United%20States&g=010XX00US]. Accessed 15 May 2024."},{"issue":"12","key":"25726_CR37","first-page":"1","volume":"72","author":"E Arias","year":"2023","unstructured":"Arias E, Xu J, Kochanek K. United States life Tables, 2021. Natl Vital Stat Rep. 2023;72(12):1\u201364.","journal-title":"Natl Vital Stat Rep"},{"issue":"19","key":"25726_CR38","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1016\/j.vaccine.2020.03.017","volume":"38","author":"L-J Chang","year":"2020","unstructured":"Chang L-J, Hedrick J, Christensen S, Pan J, Jordanov E, Dhingra MS. A phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the united States. Vaccine. 2020;38(19):3560\u20139.","journal-title":"Vaccine"},{"issue":"33","key":"25726_CR39","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: A phase III randomized study. Vaccine. 2020;38(33):5194\u2013201.","journal-title":"Vaccine"},{"issue":"3","key":"25726_CR40","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41390-023-02478-5","volume":"94","author":"B Zambrano","year":"2023","unstructured":"Zambrano B, Peterson J, Deseda C, Julien K, Spiegel CA, Seyler C, Simon M, Hoki R, Anderson M, Brabec B, et al. Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatr Res. 2023;94(3):1035\u201343.","journal-title":"Pediatr Res"},{"key":"25726_CR41","doi-asserted-by":"publisher","first-page":"127332","DOI":"10.1016\/j.vaccine.2025.127332","volume":"61","author":"X Dong","year":"2025","unstructured":"Dong X, Schillie SF, McNamara LA, Leidner AJ. Cost-effectiveness of pentavalent meningococcal (MenABCWY) vaccination among adolescents in the united States. Vaccine. 2025;61:127332.","journal-title":"Vaccine"},{"key":"25726_CR42","unstructured":"Centers for Disease Control and Prevention: Enhanced Meningococcal Disease Surveillance Report. 2018 [https:\/\/stacks.cdc.gov\/view\/cdc\/140465]. Accessed 31 May 2025."},{"key":"25726_CR43","unstructured":"Centers for Disease Control and Prevention: Enhanced Meningococcal Disease Surveillance Report. 2017 [https:\/\/stacks.cdc.gov\/view\/cdc\/140464]. Accessed 31 May 2025."},{"key":"25726_CR44","unstructured":"Centers for Disease Control and Prevention: Enhanced Meningococcal Disease Surveillance Report. 2016 [https:\/\/stacks.cdc.gov\/view\/cdc\/140469]. Accessed 31 May 2025."},{"issue":"1","key":"25726_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4161\/hv.7.1.13692","volume":"7","author":"KL Davis","year":"2011","unstructured":"Davis KL, Misurski D, Miller JM, Bell TJ, Bapat B. Cost of acute hospitalization and post-discharge follow-up care for meningococcal disease in the US. Hum Vaccin. 2011;7(1):96\u2013101.","journal-title":"Hum Vaccin"},{"key":"25726_CR46","unstructured":"United States Census Bureau. National Population by Characteristics: 2010\u20132019 [https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2010s-national-detail.html]. Accessed 1 November 2024."},{"key":"25726_CR47","unstructured":"United States Census Bureau. National Population by Characteristics: 2020\u20132023 [https:\/\/www.census.gov\/data\/tables\/time-series\/demo\/popest\/2020s-national-detail.html]. Accessed 1 November 2024."},{"issue":"5","key":"25726_CR48","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1542\/peds.2004-2514","volume":"115","author":"CW Shepard","year":"2005","unstructured":"Shepard CW, Ortega-Sanchez IR, Scott RD 2nd, Rosenstein NE. Cost-effectiveness of conjugate meningococcal vaccination strategies in the united States. Pediatrics. 2005;115(5):1220\u201332.","journal-title":"Pediatrics"},{"issue":"10","key":"25726_CR49","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, Kuntz KM, Meltzer DO, Owens DK, Prosser LA, et al. Recommendations for Conduct, methodological Practices, and reporting of Cost-effectiveness analyses: second panel on Cost-Effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103.","journal-title":"JAMA"},{"key":"25726_CR50","unstructured":"Institute for Clinical and Economic Review: ICER\u2019s Reference Case for Economic Evaluations: Principles and Rationale. Current as of January 31. 2020 [https:\/\/icer.org\/wp-content\/uploads\/2020\/10\/ICER_Reference_Case_013120.pdf]. Accessed 26 June 2024."},{"issue":"3","key":"25726_CR51","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803\u201316.","journal-title":"Qual Life Res"},{"issue":"19","key":"25726_CR52","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1016\/j.vaccine.2016.03.020","volume":"34","author":"H Lecocq","year":"2016","unstructured":"Lecocq H, Parent du Ch\u00e2telet I, Taha MK, L\u00e9vy-Bruhl D, Dervaux B. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France. Vaccine. 2016;34(19):2240\u201350.","journal-title":"Vaccine"},{"issue":"6","key":"25726_CR53","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s11136-004-7706-z","volume":"14","author":"I Koomen","year":"2005","unstructured":"Koomen I, Raat H, Jennekens-Schinkel A, Grobbee DE, Roord JJ, van Furth M. Academic and behavioral limitations and health-related quality of life in school-age survivors of bacterial meningitis. Qual Life Res. 2005;14(6):1563\u201372.","journal-title":"Qual Life Res"},{"issue":"4","key":"25726_CR54","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jinf.2010.07.006","volume":"61","author":"B Schmand","year":"2010","unstructured":"Schmand B, de Bruin E, de Gans J, van de Beek D. Cognitive functioning and quality of life nine years after bacterial meningitis. J Infect. 2010;61(4):330\u20134.","journal-title":"J Infect"},{"issue":"1","key":"25726_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/524041","volume":"46","author":"IR Ortega-Sanchez","year":"2008","unstructured":"Ortega-Sanchez IR, Meltzer MI, Shepard C, Zell E, Messonnier ML, Bilukha O, Zhang X, Stephens DS, Messonnier NE. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the united States. Clin Infect Dis. 2008;46(1):1\u201313.","journal-title":"Clin Infect Dis"},{"key":"25726_CR56","unstructured":"Federal Reserve Bank of St Louis. Consumer Price Index for All Urban Consumers: All Items in U.S. City Average [https:\/\/fred.stlouisfed.org\/series\/CPIAUCSL]. Accessed 4 May 2025."},{"key":"25726_CR57","unstructured":"Federal Reserve Bank of St Louis. Consumer Price Index for All Urban Consumers: Medical Care in U.S. City Average [https:\/\/fred.stlouisfed.org\/series\/CPIMEDSL]. Accessed 4 May 2025."},{"issue":"6","key":"25726_CR58","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/13696998.2018.1542520","volume":"22","author":"SD Grosse","year":"2019","unstructured":"Grosse SD, Krueger KV, Pike J. Estimated annual and lifetime labor productivity in the united States, 2016: implications for economic evaluations. J Med Econ. 2019;22(6):501\u20138.","journal-title":"J Med Econ"},{"issue":"29","key":"25726_CR59","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1016\/j.vaccine.2007.04.071","volume":"25","author":"P De Wals","year":"2007","unstructured":"De Wals P, Coudeville L, Trottier P, Chevat C, Erickson LJ, Nguyen VH. Vaccinating adolescents against meningococcal disease in canada: A cost-effectiveness analysis. Vaccine. 2007;25(29):5433\u201340.","journal-title":"Vaccine"},{"issue":"8","key":"25726_CR60","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/21645515.2021.1880209","volume":"17","author":"SV Watle","year":"2021","unstructured":"Watle SV, Naess LM, Tunheim G, Caugant DA, Wisloff T. Cost-effectiveness of meningococcal vaccination of Norwegian teenagers with a quadrivalent ACWY conjugate vaccine. Hum Vaccin Immunother. 2021;17(8):2777\u201387.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"25726_CR61","doi-asserted-by":"publisher","first-page":"e65036","DOI":"10.1371\/journal.pone.0065036","volume":"8","author":"H Hepkema","year":"2013","unstructured":"Hepkema H, Pouwels KB, Van Der Ende A, Westra TA, Postma MJ. Meningococcal serogroup A, C, W135 and Y conjugated vaccine: A Cost-Effectiveness analysis in the Netherlands. PLoS ONE. 2013;8(5):e65036.","journal-title":"PLoS ONE"},{"issue":"7","key":"25726_CR62","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1097\/INF.0000000000001512","volume":"36","author":"P De Wals","year":"2017","unstructured":"De Wals P, Zhou Z. Cost-effectiveness comparison of monovalent C versus quadrivalent ACWY meningococcal conjugate vaccination in Canada. Pediatr Infect Dis J. 2017;36(7):e203\u20137.","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"25726_CR63","doi-asserted-by":"publisher","first-page":"e0175721","DOI":"10.1371\/journal.pone.0175721","volume":"12","author":"TE Delea","year":"2017","unstructured":"Delea TE, Weycker D, Atwood M, Neame D, Alvarez FP, Forget E, Langley JM, Chit A. Cost-effectiveness of alternate strategies for childhood immunization against meningococcal disease with monovalent and quadrivalent conjugate vaccines in Canada. PLoS ONE. 2017;12(5):e0175721.","journal-title":"PLoS ONE"},{"issue":"1","key":"25726_CR64","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jval.2020.09.004","volume":"24","author":"E Beck","year":"2021","unstructured":"Beck E, Klint J, Neine M, Garcia S, Meszaros K. Cost-Effectiveness of 4CMenB infant vaccination in england: A comprehensive valuation considering the broad impact of serogroup B invasive meningococcal disease. Value Health. 2021;24(1):91\u2013104.","journal-title":"Value Health"},{"issue":"35","key":"25726_CR65","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1016\/j.vaccine.2019.07.008","volume":"37","author":"S Si","year":"2019","unstructured":"Si S, Zomer E, Fletcher S, Lee J, Liew D. Cost-effectiveness of meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine in Australian adolescents. Vaccine. 2019;37(35):5009\u201315.","journal-title":"Vaccine"},{"issue":"7385","key":"25726_CR66","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1136\/bmj.326.7385.365","volume":"326","author":"ME Ramsay","year":"2003","unstructured":"Ramsay ME, Andrews NJ, Trotter CL, Kaczmarski EB, Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in england: database analysis. BMJ. 2003;326(7385):365\u20136.","journal-title":"BMJ"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-25726-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-25726-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T10:18:28Z","timestamp":1770200308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12889-025-25726-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,4]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["25726"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-25726-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,4]]},"assertion":[{"value":"6 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study does not involve human participants, human data nor human tissue, as it is based on a health economic model using simulated population cohorts. Therefore, ethics approval and consent to participate were not applicable to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AU, CR, KG, MPN, and TS are employees of Sanofi and may hold stock or stock options. JW holds a co-sponsored Industrial Research Chair grant with Sanofi. OC and EC are employees of Clever-Access, a consultancy that received funding from Sanofi to conduct the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"452"}}